Coenzyme Q10 (CoQ10, ubiquinone) is a fat-soluble compound the body synthesizes and also obtains in small amounts from foods such as oily fish, organ meats, and nuts. Concentrated in the inner mitochondrial membrane, it serves as an essential electron-transport-chain cofactor for cellular ATP (energy) production and also functions as a lipid-soluble antioxidant. Ubiquinol is the fully reduced form of CoQ10; the ubiquinone and ubiquinol forms interconvert in the body as the molecule shuttles electrons, and ubiquinol has shown better oral absorption than ubiquinone in several pharmacokinetic studies. Endogenous CoQ10 levels fall with age and are further lowered by statin drugs, which inhibit a biosynthetic pathway shared with cholesterol.
In human trials CoQ10 has been studied mainly as an adjunct in cardiovascular disease: the Q-SYMBIO randomized trial reported roughly halved major adverse cardiovascular events in chronic heart failure, and a 2024 meta-analysis of 33 heart-failure trials found lower all-cause mortality (RR 0.64) and hospitalization (RR 0.50), though a Cochrane review still rates the heart-failure evidence as low certainty. Other meta-analyses suggest modest reductions in systolic blood pressure, improved flow-mediated (endothelial) dilation, and small improvements in lipids, glycemic markers, and fatigue, balanced by a Cochrane review finding no clinically significant blood-pressure effect in primary hypertension and one meta-analysis finding no benefit for statin-associated muscle pain. Ubiquinol-specific trials are fewer but intriguing: high-dose ubiquinol (1,500 mg/day) slowed functional decline in multiple system atrophy in a phase 2 trial, and small trials report improved endothelial function. Much of the mortality data (for example KiSel-10, with benefit persisting at 10 years) comes from CoQ10 combined with selenium, no trial shows CoQ10 extends lifespan in healthy people, and findings are best viewed as promising rather than definitive. This evidence describes the coenzyme Q10 compound and its mechanisms, not this specific commercial ubiquinol product.
Peer-reviewed studies on the active compound — citations link to PubMed.
“Ubiquinol led to significant improvement in peripheral endothelial function”
“significant increase in total CoQ10 levels in the ubiquinol group compared to placebo”
“CoQ10 appears to have beneficial effects in reducing duration and frequency of migraine attack.”
“However, CoQ10 was more effective than placebo in reducing migraine days/month (P < 0.00001) and migraine duration (P = 0.009).”
“CoQ10 was superior to placebo for attack-frequency, headache-days and days-with-nausea in the third treatment month and well tolerated; 50%-responder-rate for attack frequency was 14.4% for placebo and 47.6% for CoQ10 (number-needed-to-treat: 3).”
“The primary long-term endpoint was reached by 15% of the patients in the CoQ10 group versus 26% in the placebo group (hazard ratio: 0.50; 95% confidence interval: 0.32 to 0.80; p = 0.003) by intention-to-treat analysis.”
Research describes the active mechanism and is not a claim about this specific product.
Across large randomized trials and meta-analyses, marine omega-3s reliably reduce serum…
Across meta-analyses and randomized trials, creatine monohydrate combined with…
In humans, randomized trials and meta-analyses most consistently show that astaxanthin…
Multiple meta-analyses of randomized trials indicate that oral zinc, started soon after…
Yes — its active compound is linked to 27 peer-reviewed studies, summarized and cited above.
You can buy it on Amazon via the link above; Magellan earns a small affiliate commission at no extra cost to you, which does not affect the evidence grade.
Dietary supplements and devices are generally well tolerated but are not a substitute for medical care. Talk to your physician before starting, especially if you take medication or have a health condition.